INTRODUCTION {#S1}
============

B cell development requires the sequential assembly and expression of genes encoding the immunoglobin heavy (Igh) and immunoglobulin light (Igl) chains to generate a mature B cell receptor (BCR) ([@R51]). *Ig* genes are assembled through the process of V(D)J recombination, which joins distant variable (V), joining (J), and diversity (D) segments ([@R19]). The DNA double-strand breaks (DSBs) necessary for V(D)J recombination are generated by the RAG endonuclease, which is composed of the RAG1 and RAG2 proteins ([@R19]). RAG-mediated DNA breaks are generated in the G1 phase of the cell cycle and activate the DNA damage response (DDR) kinase ATM, which facilitates repair of the broken DNA ends through nonhomologous end joining ([@R23]). In response to RAG DSBs, ATM also activates a broad transcriptional program that regulates genes involved in diverse B cell functions, including migration, cell-cycle arrest, survival, and differentiation ([@R6], [@R7]; [@R10]; [@R23]; [@R68]). This genetic program is mediated by ATM-dependent activation of several transcription factors, including NF-κB1, NF-κB2, and SPIC ([@R6], [@R7]; [@R10]).

The *Igh* gene is assembled first in pro-B cells and productive rearrangement results in its surface expression with surrogate light chains (*λ*5 and VpreB) to generate the pre-BCR, which signals transition to the large pre-B cell stage ([@R13]; [@R24]; [@R51]). Pre-BCR oligomerization signals through the SYK tyrosine kinase to promote proliferation and clonal expansion of large pre-B cells ([@R13]; [@R24]). Activation of SYK also triggers *IgIκ* (*Igk*) gene recombination ([@R13]). RAG expression is suppressed in proliferating cells, and as such, *Igk* gene assembly requires induction of cell-cycle arrest and transition to the small, non-proliferating pre-B cell stage ([@R13]; [@R17]; [@R27]; [@R43]). RAG DSBs activate ATM-dependent DDR signaling pathways that enforce cell-cycle arrest and promote survival to prevent proliferation of cells with unrepaired DSBs and permit time for proper assembly of *Igk* genes ([@R6], [@R7]; [@R16]).

B cell development and assembly of *Ig* genes are carefully orchestrated by developmental stage-specific transcription factors, including E2A, EBF, Pax5, PU.1 and SPIB ([@R44]). The ETS-family transcription factor PU.1 is required for B cell lineage commitment and is constitutively expressed throughout B cell development ([@R47]; [@R61]; [@R62], [@R63]). PU.1 has critical functions during B cell maturation. In pre-B cells, PU.1 regulates expression of a diverse genetic program, including genes involved in B cell proliferation, differentiation, and *Ig* gene rearrangement ([@R5]; [@R22]; [@R67]). Expression of SYK and germline transcription of *Igk,* which are required for pre-BCR signaling and initiating V(D) J recombination, respectively, depend on PU.1 activity ([@R5]; [@R24]; [@R60]; [@R61]). Interestingly, loss of PU.1 in B cell progenitors results in only a mild defect in B cell development because of compensatory function of another ETS-family transcription factor, SPIB ([@R47]; [@R66]; [@R73]). PU.1 and SPIB associate with nearly identical regions of the genome in B cells and regulate transcription of a similar cohort of genes ([@R67]). Combined loss of PU.1 and SPIB impairs B cell maturation in the bone marrow and predisposes to the development of B cell leukemia ([@R66]).

We previously demonstrated that SPIC, an ETS-family transcriptional repressor with homology to PU.1 and SPIB, also functions in pre-B cells ([@R7]; [@R8]; [@R21]). Unlike PU.1 and SPIB, SPIC is not constitutively expressed in early B cells but, rather, is induced by signals from RAG DSBs ([@R7]). SPIC operates primarily as a transcriptional repressor and counters the activating functions of PU.1 and SPIB ([@R33]; [@R76]). In pre-B cells, SPIC suppresses expression of *Syk* and *Blnk,* which inhibits pre-BCR signaling and enforces cell-cycle arrest in pre-B cells with RAG DSBs ([@R7]). SPIC also inhibits transcription of *Igk* to prevent generation of additional RAG DSBs ([@R7]). Binding of SPIC to gene-regulatory elements for *Syk, Blnk,* and *Igk* is associated with loss of PU.1 at these genomic regions. Thus, expression of SPIC antagonizes PU.1 as these identified genes to suppress transcription and coordinate pre-B cell development.

Whether SPIC has broader functions in gene regulation and its mechanism of action in B cells have not been defined. SPIC may oppose PU.1 at limited gene targets or, alternatively, may modulate PU.1 activity throughout the genome. In this regard, attenuation of PU.1 activity by SPIC could suppress pre-B cell genetic programs to promote continued B cell maturation. SPIC may function simply by displacing PU.1 through competition for DNA binding sites or may complex with other transcriptional regulators to repress transcription. We show here that, in response to RAG DSBs, SPIC binds throughout the genome of pre-B cells and elicits global changes in PU.1 chromatin association. SPIC associates with the transcriptional repressor BCLAF1 (Bcl2-associated factor 1) to regulate a distinct subset of RAG DSB-dependent gene expression changes and to enforce transition from large to small pre-B cells. These experiments provide insight into the regulation of ETS transcription factors in early B cells and the impact of DDR signaling on B cell development.

RESULTS {#S2}
=======

RAG DSB Signals Induce Genome-Wide Changes in PU.1 Binding {#S3}
----------------------------------------------------------

To determine the effects of DNA damage signaling on PU.1 activity in early B cells, we used Abelson-kinase transformed pre-B cells (abl pre-B cells) deficient in RAG1 or the Artemis endonuclease that express the *Bcl2* transgene (*Rag1*^−/−^*:Bcl2* and *Art*^−/−^*:Bcl2,* respectively) ([@R10]). Expression of the Abl kinase promotes pre-B cell proliferation and suppresses expression of *Rag1* and *Rag2.* Treatment with the Abl kinase inhibitor imatinib triggers cell-cycle arrest, induction of RAG expression, and recombination of *Igk* ([@R10]). The *Bcl2* transgene supports survival of imatinib-treated cells. Following treatment with imatinib, *Rag1*^−/−^*:Bcl2* abl pre-B cells do not generate RAG DSBs. In contrast, *Art*^−/−^*:Bcl2* abl pre-B cells generate RAG DSBs at *Igk*, but these DSBs are not repaired as Artemis is required to open hairpin-sealed coding DNA ends ([Figure 1A](#F1){ref-type="fig"}) ([@R10]; [@R23]). The RAG DSBs in *Art*^−/−^*:Bcl2* abl pre-B cells activate ATM-dependent DDRs ([@R6], [@R7]; [@R10]).

Chromatin immunoprecipitation followed by next-generation DNA sequencing (ChIP-seq) reveals global changes in PU.1 binding in pre-B cells with RAG DSBs (*Art*^−/−^*:Bcl2*) compared with pre-B cells without RAG DSBs (*Rag1*^−/−^*:Bcl2*), despite no differences in PU.1 expression ([Figures 1B](#F1){ref-type="fig"}, [1C](#F1){ref-type="fig"}, and [S1A](#SD1){ref-type="supplementary-material"}). Induction of RAG DSBs results in gain of few new binding sites but loss of approximately 20% of the PU.1 binding sites identified in *Rag1*^−/−^*:Bcl2* abl pre-B cells ([Figure 1B](#F1){ref-type="fig"}). Gene Ontology analysis demonstrates that genes within 12 kb of lost PU.1 binding sites are involved in immune cell activation and differentiation ([Figure S1B](#SD1){ref-type="supplementary-material"}). In contrast, PU.1 binding sites that are conserved between *Rag1*^−/−^*:Bcl2* and *Art*^−/−^*:Bcl2* abl pre-B cells are proximal to genes involved in cell homeostasis and maintenance (i.e., signaling, nuclear transport, apoptosis). Novel RAG DSB-induced PU.1 binding occurred near genes involved in cell adhesion and developmental processes. Induction of RAG DSBs did not alter PU.1 binding across genomic regulatory elements as equal binding to promoters, genes, or intergenic regions (i.e., enhancers) is observed in both *Rag1*^−/−^*:Bcl2* and *Art*^−/−^*:Bcl2* abl pre-B cells ([Figure S1C](#SD1){ref-type="supplementary-material"}). Thus, in response to RAG DSBs, pre-B cells have a genome-wide reduction in PU.1 chromatin binding, which is expected to result in changes in gene expression that affect important cellular functions.

Expression of SPIC Alters PU.1 Binding in Pre-B Cells {#S4}
-----------------------------------------------------

RAG DSBs trigger ATM-dependent induction of SPIC ([Figure 2A](#F2){ref-type="fig"}). Expression of SPIC, in turn, results in loss of PU.1 binding at genes required for pre-BCR signaling ([@R7]). To determine if expression of SPIC is responsible for the global changes in PU.1 binding observed in response to RAG DSBs, we stably transduced *Rag1*^−/−^*:Bcl2* abl pre-B cells with a lentiviral vector encoding a tetracycline-inducible FLAG-HA-tagged SPIC (*Rag1*^−/−^*:Bcl2:Spic*^*tet*^). Treatment with doxycycline induced equivalent SPIC mRNA expression as triggered by RAG DSBs ([Figures 2A](#F2){ref-type="fig"} and [2B](#F2){ref-type="fig"}). We performed ChIP-seq for PU.1 in *Rag1*^−/−^*:Bcl2:Spic*^*tet*^ abl pre-B cells treated with imatinib alone or in combination with doxycycline to induce expression of SPIC ([Figure 2B](#F2){ref-type="fig"}). Expression of SPIC does not alter PU.1 expression but results in significant changes in PU.1 chromatin binding ([Figures 2C](#F2){ref-type="fig"} and [2D](#F2){ref-type="fig"}). Moreover, expression of SPIC results in changes in PU.1 binding that are similar to changes induced by RAG DSBs (compare [Figures 1B](#F1){ref-type="fig"} and [2D](#F2){ref-type="fig"}). These findings demonstrate that changes in PU.1 binding in response to RAG DSBs are, in large part, due to RAG DSB-mediated induction of SPIC.

SPIC and PU.1 Bind to Identical Genomic Regions {#S5}
-----------------------------------------------

SPIC and PU.1 have homologous DNA binding domains and have been previously shown *in vitro* to bind to the same DNA sequence ([@R8]; [@R21]). Current commercial antibodies against endogenous SPIC do not work for ChIP. Thus, to determine if SPIC and PU.1 binding to chromatin is similarly distributed throughout the genome, we performed ChIP-seq with anti-HA antibodies to precipitate FLAG-HA-SPIC in *Rag1*^−/−^*:Bcl2:Spic*^*tet*^ abl pre-B cells treated with doxycycline (to induce SPIC). Results were compared with findings from ChIP-seq for PU.1 in *Rag1*^−/−^*:Bcl2* abl pre-B cells without SPIC expression. Peaks with ≥1 bp of overlap between the two ChIP-seq datasets were considered as enriched for binding to both transcription factors. We find that SPIC and PU.1 bind to similar locations throughout the genome ([Figure 3A](#F3){ref-type="fig"}). Additionally, PU.1 binding is lost at sites where SPIC is bound ([Figures 3B](#F3){ref-type="fig"}, [3C](#F3){ref-type="fig"}, and [S2](#SD1){ref-type="supplementary-material"}).

The ChIP peaks for SPIC and PU.1 in regions where both transcription factors bind (common peaks in [Figure 3A](#F3){ref-type="fig"}) have significant nucleotide overlap ([Figures 3D](#F3){ref-type="fig"}). Indeed, the majority of these shared binding sites overlap by \>70%, and the greatest number of ChIP peaks have \>90% overlap. Furthermore, SPIC and PU.1 bind to similar regions throughout the genome ([Figure 3E](#F3){ref-type="fig"}). Collectively, these findings demonstrate that SPIC and PU.1 bind to similar regulatory elements in pre-B cells and that SPIC binding results in displacement of PU.1 from these regions.

SPIC Recruits BCLAF1 to Chromatin {#S6}
---------------------------------

PU.1 forms heterodimeric complexes with IRF4 or IRF8 to regulate transcription initiation ([@R9]; [@R22]). SPIC does not complex with IRF4 or IRF8 but binds to similar DNA sequences as PU.1 ([@R12]). These findings raise the question of whether SPIC complexes with distinct protein partners to regulate gene expression. To identify SPIC interacting partners, we generated *Art*^−/−^*:Bcl2* abl pre-B cells expressing either a tetracycline-inducible FLAG-HA-tagged SPIC (*Art*^−/−^*:Bcl2:Spic*^*tet*^) or a tetracycline-inducible FLAG-HA-tagged PU.1 (*Art*^−/−^*:Bcl2:Pu1*^*tet*^). Cells were treated with imatinib to induce RAG DSBs and with doxycycline to induce comparable expression of the FLAG-tagged transcription factors ([Figure S3](#SD1){ref-type="supplementary-material"}). SPIC and PU.1 were immunoprecipitated using anti-FLAG antibodies, and associated proteins were identified by tandem mass spectrometry. Unique peptides were compared with identify proteins enriched for binding to SPIC ([Figure 4A](#F4){ref-type="fig"}; [Table S1](#SD2){ref-type="supplementary-material"}). We focused on nuclear proteins with functions in transcriptional regulation. One of these proteins that enriched for binding to SPIC and not PU.1 is BCLAF1 ([Figures 4A](#F4){ref-type="fig"} and [4B](#F4){ref-type="fig"}). BCLAF1 was originally identified as a transcriptional repressor but has also been shown to promote gene expression in response to DNA damage ([@R28]; [@R34]; [@R65]). *Bclaf1*-deficient mice have reduced T cells and increased splenic B cell numbers, suggesting that BCLAF1 may function in immune development ([@R38]).

Reciprocal co-immunoprecipitation experiments demonstrate that BCLAF1 selectively associates with SPIC and not PU.1 in *Art*^−*/*−^*:Bcl2* abl pre-B cells ([Figures 4B](#F4){ref-type="fig"} and [4C](#F4){ref-type="fig"}). In contrast, IRF4 and IRF8 associate with PU.1 but do not complex with SPIC ([Figure 4B](#F4){ref-type="fig"}). To determine if BCLAF1 is recruited to SPIC-bound chromatin in pre-B cells, we compared BCLAF1 ChIP-seq with SPIC ChIP-seq. A significant portion (\>80%) of BCLAF1 and SPIC peaks overlap indicating that the two proteins associate with similar chromatin regions ([Figure 4D](#F4){ref-type="fig"}). Consistent with ChIP-seq results, BCLAF1 binding to the *Syk* promoter is increased in cells expressing SPIC ([Figure 4E](#F4){ref-type="fig"}). Additionally, ChIP-re-ChIP experiments show that BCLAF1 only associates with the SPIC-bound *Syk* promoter and not with the PU.1-bound promoter ([Figure 4F](#F4){ref-type="fig"}). Finally, BCLAF1 binding to the *Syk* promoter is increased in pre-B cells with RAG DSBs (*Art*^−/−^*:Bcl2*), which express SPIC ([Figures 4G](#F4){ref-type="fig"} and [2A](#F2){ref-type="fig"}). BCLAF1 ChIP peaks contain the conserved ETS DNA binding sequence (GGAA, p \< 1 × e^−33^) suggesting that it may not directly bind DNA but rather is recruited to chromatin by SPIC in response to RAG DSBs in pre-B cells.

SPIC and BCLAF1 Regulate Gene Expression in Pre-B Cells {#S7}
-------------------------------------------------------

We previously showed that in response to RAG DSBs, SPIC represses expression of key genes required for pre-BCR signaling ([@R7]). Given our current findings that SPIC and its partner BCLAF1 bind throughout the genome, we hypothesized that this complex regulates a broad genetic program in pre-B cells. To identify the genes regulated by SPIC, we compared transcriptional changes in *Rag1*^−/−^*:Bcl2:Spic*^*tet*^ abl pre-B cells with and without expression of SPIC. Expression of 866 genes was changed ≥ 2-fold (adjusted p \< 0.05) following expression of SPIC ([Figures 5A](#F5){ref-type="fig"} and [S4A](#SD1){ref-type="supplementary-material"}; [Table S2](#SD3){ref-type="supplementary-material"}). Knockdown of BCLAF1 in SPIC-expressing *Rag1*^−/−^*:Bcl2:Spic*^*tet*^ abl pre-B cells changes expression of 55% of SPIC-regulated genes (≥ 2-fold change, adjusted p \< 0.05) ([Figures 5B](#F5){ref-type="fig"}, [5C](#F5){ref-type="fig"}, and [S4A](#SD1){ref-type="supplementary-material"}; [Table S2](#SD3){ref-type="supplementary-material"}). Notably, genes repressed by SPIC were rescued following knockdown of BCLAF1 ([Figures 5C](#F5){ref-type="fig"} and [S4A](#SD1){ref-type="supplementary-material"}). Gene Ontology analysis revealed that SPIC- and BCLAF1-dependent genes are enriched for immune processes in B cells ([Figure S4B](#SD1){ref-type="supplementary-material"}). Importantly, loss of BCLAF1 does not alter SPIC binding to the *Syk* promoter, suggesting that recruitment of BCLAF1 is needed for SPIC-mediated transcriptional changes but not for SPIC binding to chromatin ([Figure 5D](#F5){ref-type="fig"}).

We then determined the contribution of SPIC/BCLAF to the genetic program regulated by RAG DSBs in pre-B cells. Gene profiling revealed that BCLAF1 regulates a significant portion of RAG DSB-mediated genes (540 of 717 genes, ≥2-fold change, adjusted p \< 0.05; [Figure 5E](#F5){ref-type="fig"}; [Table S3](#SD4){ref-type="supplementary-material"}). Comparison of RAG DSB-dependent (*Art*^−/−^*:Bcl2* versus *Rag1*^−/−^*:Bcl2;* [Figure 5E](#F5){ref-type="fig"}), SPIC-dependent (*Rag1*^−/−^*:Bcl2:Spic*^*tet*^ expressing SPIC versus *Rag1*^−/−^*:Bcl2;* [Figure 5A](#F5){ref-type="fig"}), and BCLAF1-dependent (*Art*^−/−^*:Bcl2* expressing shBCLAF1 versus *Art*^−/−^*:Bcl2;* [Figure 5E](#F5){ref-type="fig"}) gene expression changes identified 141 genes whose expression is modulated by all three variables ([Figures 5F](#F5){ref-type="fig"}, [5G](#F5){ref-type="fig"}, and [S5A](#SD1){ref-type="supplementary-material"}; [Table S4](#SD1){ref-type="supplementary-material"}). Approximately 25% of these genes have concordant changes in expression (repressed by RAG DSBs, repressed by SPIC, and rescued by loss of BCLAF1; [Figure S5A](#SD1){ref-type="supplementary-material"}). Pathway analyses are enriched for diverse B cell functions, including proliferation, cell adhesion, and cell death ([Figure S5B](#SD1){ref-type="supplementary-material"}). These findings demonstrate that the SPIC/BCLAF1 complex regulates a distinct genetic program in pre-B cells with RAG DSBs.

BCLAF1 Regulates Pre-BCR Signaling in Primary Pre-B Cells {#S8}
---------------------------------------------------------

To determine if BCLAF1 is required for regulation of SPIC function in primary pre-B cells, we expanded pre-B cells from *Rag1*^−/−^*:μIgh:Bcl2* and *Art*^−/−^*:μIgh:Bcl2* mice in the presence of interleukin-7 (IL-7) ([@R6], [@R7]). The *μIgh* transgene permits expression of a pre-BCR, which promotes transition to the pre-B cell developmental stage ([@R6], [@R7]). IL-7 promotes proliferation and expansion of large pre-B cells. Withdrawal of IL-7 induces cell-cycle arrest, transition to small pre-B cells, expression of RAG, and induction of RAG DSBs at *Igk* ([@R6], [@R7]; [@R27]; [@R43]; [@R54]; [@R68]). Consistent with our previous findings, withdrawal of IL-7 results in induction of SPIC and suppression of *Syk* transcripts in pre-B cells with RAG DSBs *(Art*^−/−^*:μIgh:Bcl2)* ([Figures 6A](#F6){ref-type="fig"} and [6B](#F6){ref-type="fig"}) ([@R7]). Loss of BCLAF1 does not alter induction of *Spic* but does lead to increased expression of *Syk* in *Art*^−/−^*:μIgh:Bcl2* small pre-B cells ([Figures 6A](#F6){ref-type="fig"} and [6B](#F6){ref-type="fig"}). Consistent with the rescue of *Syk* mRNA levels, SYK protein is increased in *Art*^−/−^*:Igh:Bcl2* pre-B cells lacking BCLAF1 to levels equivalent to those observed in *Rag1*^−/−^*:μIgh:Bcl2* pre-B cells ([Figure 6C](#F6){ref-type="fig"}). On the basis of these results, we conclude that BCLAF1 is necessary for repression of SYK in response to RAG DSBs in primary small pre-B cells.

To assess BCLAF1 binding to the *Syk* promoter during wild-type pre-B cell development *in vivo,* we used *Spic*^*igfp/igfp*^ mice, which contain an IRES-EGFP targeted to the 3′ non-coding exon of *Spic* ([@R20]). Approximately 2% of small pre-B cells from *Spic*^*igfp/igfp*^ mice are EGFP positive, indicative of SPIC expression ([Figures 6D](#F6){ref-type="fig"} and [6E](#F6){ref-type="fig"}). EGFP-expressing small pre-B cells are not observed in *Atm*^*−*/*−*^*:Spic*^*igfp/igfp*^, indicating that induction of SPIC (and EGFP) depends on DNA damage signaling ([Figure 6E](#F6){ref-type="fig"}). SPIC-expressing *Spic*^*igfp/igfp*^ small pre-B cells (EGFP positive) have reduced PU.1 binding and increased BCLAF1 binding to the *Syk* promoter as well as decreased *Syk* expression ([Figures 6F](#F6){ref-type="fig"}--[6H](#F6){ref-type="fig"}) ([@R7]). These results suggest that SPIC/BCLAF1 complex is induced by DNA damage signals from transient RAG DSBs generated during *Igl* rearrangement in wild-type small pre-B cells.

Loss of BCLAF1 Alters Large to Small Pre-B Cell Transition {#S9}
----------------------------------------------------------

Activation of SYK downstream of the pre-BCR can promote pre-B cell proliferation in the absence of IL-7 signaling ([@R13]; [@R24]; [@R43]; [@R55]; [@R72]). Given that loss of BCLAF1 prevents SPIC-mediated repression of SYK, we hypothesized that loss of BCLAF1 may alter pre-B cell proliferation and the transition from large to small pre-B cells during early B cell development. To test this, we generated *Bclaf1*^*f/f*^*:Mb1-cre* mice, which have selective loss of BCLAF1 in B cells ([Figure 7A](#F7){ref-type="fig"}) ([@R25]). Pre-B cells from *Bclaf1*^*f/f*^*:Mb1-cre* and *Bclaf1*^*f/f*^ mice were expanded in the presence of IL-7. Following IL-7 withdrawal, *Bclaf1*-deficient pre-B cells from *Bclaf1*^*f/f*^*:Mb1-cre* mice have increased S-phase progression and increased *Syk* expression compared with pre-B cells from *Bclaf1™* and *Mb1-cre* mice ([Figures 7B](#F7){ref-type="fig"}--[7D](#F7){ref-type="fig"}). These findings support a role for BCLAF1 in the regulation of pre-B cell proliferation possibly through modulation of SYK activity downstream of pre-BCR signaling.

We next assessed B cell populations *in vivo.* In our breeding, *Mb1-cre* mice have normal numbers of pro-B cells but reduced pre-B cells relative to littermate wild-type *Bclaf1*^*f/f*^ mice ([Figures 7E](#F7){ref-type="fig"} and [S6](#SD1){ref-type="supplementary-material"}). In contrast, *Bclaf1*^*f/f*^*:Mb1-cre* mice have increased numbers of pre-B cells compared with *Mb1-cre* mice and are similar to *Bclaf1*^*f/f*^ mice ([Figure 7E](#F7){ref-type="fig"}). Interestingly, the increase in pre-B cells in *Bclaf1*^*f/f*^*:Mb1-cre* mice is due primarily to larger numbers of large pre-B cells ([Figure 7E](#F7){ref-type="fig"}). Loss of *Bclaf1* does not alter numbers of pro-B cells or small pre-B cells. Consistent with findings in cultured cells, *in vivo* large, proliferating pre-B cells from *Bclaf1*^*f/f*^*:Mb1-cre* mice have increased *Syk* mRNA levels ([Figure 7F](#F7){ref-type="fig"}). *Syk* expression is not altered in small pre-B cells ([Figure 7F](#F7){ref-type="fig"}). We propose that BCLAF1 functions in response to RAG DSBs in pre-B cells to suppress *Syk* and enforce transition from the large to small pre-B cell developmental stage.

DISCUSSION {#S10}
==========

Here we show that RAG DSBs induce genome-wide changes in PU.1 localization and function, which coordinates a distinct genetic program in B cells undergoing *Ig* gene rearrangement. This modulation of PU.1 activity is mediated by RAG DSB activation of a SPIC/BCLAF1 transcriptional repressor complex. SPIC displaces PU.1 at gene regulatory sites but requires association with BCLAF1 to suppress transcription. This antagonistic function of SPIC/BCLAF1 coordinates a broad genetic program and enforces transition from large to small pre-B cells in response to RAG DSBs.

PU.1 is a key regulator of cell fate decisions during early hematopoiesis and is essential for generating B cells from hematopoietic progenitors ([@R14]; [@R15]; [@R46]; [@R62], [@R63]). PU.1 expression is high in myeloid cells, in which it is required to promote lineage specific gene expression ([@R22]). In contrast, PU.1 expression is reduced during B cell differentiation and remains low in established B cells ([@R4]; [@R42]). This differential activity of PU.1 is critical for directing appropriate lineage commitment. Dysregulation of PU.1 expression leads to aberrant differentiation and can result in leukemic transformation ([@R2]; [@R45]; [@R56], [@R57]; [@R66]). PU.1 activity is also regulated through interaction with other transcription factors, which modulate its DNA binding properties or its transcriptional function ([@R37]; [@R41]; [@R53]). For example, in early lymphoid precursors, E2A association with PU.1 inhibits PU.1-induced transcription of myeloid genes and promotes B lymphoid differentiation ([@R53]). We find that PU.1 activity is regulated at the pre-B cell developmental stage through RAG DSB-mediated induction of SPIC, which binds chromatin and displaces PU.1. This transcription factor exchange results in changes in expression of genes involved in pre-BCR signaling, B cell proliferation, and B cell differentiation.

SPIC and PU.1 have homologous DNA binding domains ([@R8]; [@R21]). As such, SPIC can compete for DNA binding sites occupied by PU.1, and binding of SPIC results in displacement of PU.1 from these sites. Interestingly, SPIC associates with \>90% of the PU.1 sites, but PU.1 binding is lost at only approximately 20% of the regions it binds in the absence of SPIC expression ([Figures 2D](#F2){ref-type="fig"} and [3A](#F3){ref-type="fig"}). It is conceivable, then, that SPIC and PU.1 may simultaneously bind specific regions of the genome, and SPIC binding may not always fully displace PU.1. Rather, binding of SPIC nearby PU.1 may alter PU.1 transcriptional activity or other transcriptional machinery at these sites. Alternatively, in an individual cell, each ETS site may be occupied by either SPIC or PU.1, but ChIP analysis on a bulk population is not sensitive enough to discriminate between these two different states.

In early B cells, PU.1 and SPIB are constitutively expressed and have complementary functions ([@R61]; [@R62], [@R63]; [@R66]; [@R67]). As such, conditional deletion of either PU.1 or SPIB alone mildly alters B cell development, but loss of both transcription factors results in a block in B cell differentiation at the pro-B cell stage ([@R47]; [@R66]; [@R70]; [@R73]). PU.1 and SPIB bind to similar regions throughout the genome of pro-B cells and regulate expression of key developmental genes, including *Syk* and *Blnk,* which are necessary for pre-BCR signaling and induction of proliferation of large pre-B cells ([@R67]). We find that SPIC also binds to the same genomic sites as PU.1. Given that SPIB and PU.1 bind identical regions and have complementary functions in early B cells, SPIC is also expected to counter SPIB similar to our observed results for PU.1. In contrast to PU.1 and SPIB, SPIC is inducibly expressed in pre-B cells in response to RAG DSBs and functions primarily as a transcriptional repressor. Expression of SPIC opposes PU.1 and SPIB activity resulting in suppression of pre-BCR and BCR signaling in early B cells and mature B cells, respectively, leading to a block in B cell maturation or function ([@R7]; [@R76]). Importantly, complete or permanent inhibition of PU.1 and SPIB could be detrimental to B cell development, as combined loss of these transcription factors results in leukemic transformation ([@R66]). In this regard, induced expression of SPIC by RAG DSBs permits for stage-specific and transient inhibition of PU.1 (and SPIB). SPIC expression is expected to be lost after RAG DSBs are repaired and associated DDR signaling is terminated. The reduction in SPIC would allow PU.1 (and SPIB) to rebind to chromatin and resume transcriptional activities necessary for mature B cell function. Thus, RAG DSBs regulate a temporary suppression of PU.1 to promote transition from large to small pre-B cells and then permit continued transition to antibody-producing mature B cells.

PU.1 forms heterodimeric complexes with IRF4 or IRF8 to promote transcription ([@R9]; [@R22]; [@R48]). As such, combined loss of IRF4 and IRF8 results in similar abnormalities in B cell development as loss of PU.1 ([@R35]; [@R36]). SPIC binds the same DNA sequence as PU.1 but has a distinct protein-interaction domain and does not bind IRF4 or IRF8 ([@R12]). Thus, SPIC could mediate suppression of transcription simply through displacement of PU.1 and loss of associated transcription activation machinery (i.e., IRF4). Displacement of the PU.1/IRF4 complex alone, though, may be insufficient to repress transcription as this is not expected to result in rapid changes in histone modifications or RNA polymerase activity, which drive gene expression. Alternatively, in a manner similar to PU.1, SPIC may effect transcriptional inhibition by recruiting additional proteins to gene-regulatory elements. In this regard, we find that SPIC, but not PU.1, binds BCLAF1. BCLAF1 is not necessary for SPIC binding to chromatin but is required for transcriptional repression. On the basis of these findings, we propose that antagonism of PU.1 activity is mediated by a SPIC-BCLAF1 complex that binds to chromatin and suppresses key PU.1-regulated genes. Further studies are needed to determine the mechanism by which the SPIC-BCLAF1 complex regulates transcription (i.e., activity on histone epigenetics, RNA polymerase activity, and locus accessibility).

BCLAF1 was first identified as a transcriptional repressor but also functions as an activator to promote expression of p53 and cytokines in response to DNA damage ([@R28]; [@R34]; [@R65]). BCLAF1 also has been identified as a component of the RNA splicing complex ([@R59]; [@R71]). We find that in early B cells, BCLAF1 complexes with SPIC to repress gene expression in response to RAG-mediated DSBs. BCLAF1 chromatin binding nearly completely overlaps with SPIC-bound genomic regions. SPIC and BCLAF1 could bind DNA independently and then cooperatively suppress transcription. In this regard, *in vitro* studies have shown that BCLAF1 binds the interferon-stimulated response element (ISRE) ([@R49]). The sequence for binding of the PU.1/IRF4 heterodimer contains a portion of the ISRE site in series with an ETS motif. BCLAF1 and SPIC could bind this same sequence, or, alternatively, BCLAF1 may be recruited to gene regulatory regions through protein-protein interactions with SPIC, which binds ETS DNA sequences. The domains that govern SPIC and BCLAF1 protein interactions and DNA binding are currently being investigated.

We find that loss of BCLAF1 prevents RAG DSB- and SPIC-mediated repression of *Syk* mRNA expression. SYK is a key signaling molecule downstream of the pre-BCR and is required for the pre-BCR to promote proliferation of large pre-B cells ([@R13]; [@R24]). We previously showed that in response to RAG DSBs, induction of SPIC suppresses pre-BCR signaling to enforce cell-cycle arrest in small pre-B cells ([@R7]). Thus, loss of BCLAF1 is expected to mitigate RAG DSB-induced inhibition of proliferation. Indeed, *Bclaf1*-deficient pre-B cells have increased cell cycle entry, and mice with B cell-specific deletion of BCLAF1 have increased numbers of proliferating, large pre-B cells, consistent with increased SYK activity. Loss of BCLAF1 does not result in a complete block in B cell development, which may reflect that additional mechanisms, such as p53, exist to regulate G1 arrest in small pre-B cells undergoing *Ig* gene rearrangement.

In summary, we find that SPIC/BCLAF1 functions to modulate PU.1 activity in pre-B cells. High activity of PU.1 promotes proliferation and expansion of large pre-B cells. As cells transition to small pre-B cell stage and initiate *Igl* gene assembly, RAG DSBs induce expression of SPIC, which partners with BCLAF1, to oppose PU.1 activity resulting in gene expression changes, including suppression of *Syk*, that promote transition from large to small pre-B cells. After rearrangement of *Igl* is completed and DSBs are repaired, termination of DDR signaling would result in cessation of SPIC/BCLAF1 activity and reestablishment of PU.1 transcriptional activation, which could support BCR signaling to drive transition to the immature B cell stage. We propose that RAG DSB-dependent activation of SPIC/BCLAF1 functions as rheostat to titer PU.1 activity during early B cell development.

STAR★METHODS {#S11}
============

LEAD CONTACT AND MATERIALS AVAILABILITY {#S12}
---------------------------------------

Further information and request for resources and reagents should be directed to the Lead Contact, Jeff Bednarski (<bednarski_j@wustl.edu>). All unique/stable reagents, including plasmids and mouse lines, are available from the Lead Contact with a completed Materials Transfer Agreement.

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S13}
--------------------------------------

***Mice***: All mice were bred and maintained under specific pathogen-free conditions at the Washington University School of Medicine and were handled in accordance to the guidelines set forth by the Division of Comparative Medicine of Washington University. *Mb1-cre* (*cd79a*^*tm1*(*cre*)*Reth*^) mice were purchased from The Jackson Laboratory. *Bclaf1*^*f/f*^ mice were generated by the trans-NIH Knock-Out Mouse Project (KOMP) and obtained from the KOMP Repository ([www.komp.org](http://www.komp.org/)). *Rag1*^−/−^*:μIgh:Bcl2* and *Art*^−/−^*:μIgh:Bcl2* were generated as previously described ([@R6], [@R7]). *Spic*^*igfp/igfp*^ (*Spic*^*tm2.1Kmm*^) were kindly provided by K. M. Murphy ([@R20]). *Spic*^*igfp/igfp*^, *Mb1-cre, Bclaf1*^*f/f*^ and *Bclaf1*^*f/f*^*:Mb1-cre* mice are on a B6 background. All other mice are on a mixed genetic background. Both sexes were used equivalently in all experiments. *In vivo* studies were conducted on 4--5 week old mice.

### Cell Lines and Primary Cultures {#S14}

*Rag1*^−/−^*:Bcl2* and *Art*^−/−^*:Bcl2* abl pre-B cells were a gift from Barry Sleckman. Cell lines were authenticated by genotyping. To induce cell cycle arrest and induction of RAG DSBs, cell lines were treated with 3 μM imatinib for indicated times ([@R10]). Primary pre-B cell cultures were generated by culturing bone marrow from 4--6 week old mice at 2 × 10^6^ cells/mL in media containing 5 ng/mL of IL-7 (Miltenyi Biotec) for 7--10 days ([@R6], [@R7]). Both sexes were used equivalently in all experiments. For IL-7 withdrawal experiments, cells were resuspended in media without IL-7 and maintained at 2 × 10^6^ cells/mL for the indicated times. ATM inhibitor KU55933 (15 μM; Tocris) was added to cultures at time of addition of imatinib or IL-7 withdrawal.

METHOD DETAILS {#S15}
--------------

### cDNA Expression and shRNA-Mediated Knock-down {#S16}

cDNAs for SPIC and PU.1 with 5′ FLAG-HA tag were individually cloned into the pFLRU-TRE-Ubc-rtTA-IRES-Thy1.2 lentiviral vector. shRNA targeting *Bclaf1* (sequence: 5′-CCTCATAGTCCTTCAC CTATT-3′) was cloned into the MSCV-hCD2-mir30 vector ([@R6]). Retrovirus was produced in platE cells by transfection of the retroviral plasmid with Lipofectamine 2000 (Life Technologies) according to the manufacturer's protocol. Lentivirus was produced in 293T cells by transfection of the lentiviral plasmid along with pCMV-VZV-G and pCMV-d8.2R plasmids with Lipofectamine 2000 ([@R69]). Viral supernatant was collected and pooled from 24--72 hours after transfection. Viral supernatant was used immediately to transduce cells or was concentrated prior to transduction. To concentrate viral particles, PEG-8000 (Sigma; final concentration 8%) was added to viral supernatant followed by incubation at 4°C overnight and centrifugation at 2500 RPM for 20 minutes. Precipitated virus was resuspended at 300x concentration in sterile PBS. Pre-B cells were transduced with unconcentrated virus (10 × 10^6^ cells in 1 mL viral supernatant) or with concentrated virus (40 × 10^6^ in 1 mL with 10x viral particles) in media with polybrene (5 μg/ml; Sigma) by centrifugation for 90 min at 1300 RPM at room temperature. Four hours later fresh media was added and the cells were incubated overnight. Virus-containing media was removed and cells were cultured in fresh media (2 × 10^6^/ml). Cells expressing the retrovirus construct were identified by flow cytometric assessment of hCD25 or hCD2 expression using a FACSCalibur (BD Biosciences). Transduced cells were sorted using biotin conjugated anti-hCD2 or anti-hCD25 (BD Biosciences) and anti-biotin magnetic beads (Miltenyi Biotec) on MS columns (Miltenyi Biotec) according to the manufacturer's protocol.

### Flow Cytometric Analyses and Cell Sorting {#S17}

Flow cytometric analyses were performed on a FACSCalibur or BD LSRFortessa (BD Biosciences). Sorting was conducted on a Sony Sy3200 through the Siteman Cancer Center Flow Cytometry Core Facility. Fluorescein isothiocyanate (FITC)-conjugated anti-CD45R/B220 (clone RA3--6B2), phycoerythrin (PE)-conjugated anti-CD43 (clone S7), FITC-conjugated anti-CD43 (clone S7), PE-Cy7-conjugated anti-CD45/B220 (clone RA3--6B2), allophycocyanin (APC)-conjugated anti-IgM (clone II/41), APC-conjugated anti-hCD2, and PE-conjugated anti-hCD2 were purchased from BD Biosciences. PE-conjugated anti-hCD25 (clone BC96) and APC-conjugated anti-hCD25 (clone BC96) were purchased from BioLegend.

### Cell Cycle Analysis {#S18}

To assess pre-BCR driven proliferation, pre-B cells were resuspended in media without IL-7 and maintained at 2 × 10^6^ cells/mL. Twenty-four hours after removal from IL-7 cells were pulsed BrdU for two hours using the BrdU-FITC kit (BD Biosciences) per the manufacturer's instructions. DNA content was assessed by 7AAD (BD Biosciences).

### Western Blot {#S19}

Western blots were done on whole cell lysates ([@R7]). Anti-SYK (clone D1I5Q) and anti-GAPDH (clone D16H11) antibodies were from Cell Signaling Technology. Anti-BCLAF1 antibody (A300--608A) was from Bethyl Laboratories. Anti-PU.1 (PA5--17505) was from Thermo Fisher Scientific. Anti-FLAG (clone M2) was from Sigma. Secondary reagents were horseradish peroxidase (HRP)-conjugated anti-mouse IgG (Cell Signaling; catalog \# 7076) or anti-rabbit IgG (Cell Signaling; catalog \# 7074). Westerns were developed with ECL (Pierce) and ECL Prime (GE Healthcare).

### RT-PCR {#S20}

For genomic DNA isolation, cells were lysed in lysis buffer (100 mM TRIS pH8.5, 5 mM EDTA, 200mM NaCl and 0.2% SDS) and DNA was precipitated by addition of isopropanol, washed with 70% ethanol and then resuspended in Tris-EDTA buffer ([@R10]). RNA was isolated using RNeasy (QIAGEN) and reversed transcribed using a polyT primer with SuperScriptII (Life Technologies) according to the manufacturers' protocol. RT-PCR was performed using Brilliant II SYBR Green (Agilent) and acquired on an Mx3000P (Stratagene). Each reaction was run in triplicate. Values were normalized to housekeeping genes as indicated, and fold change was determined by the ΔΔ cycle threshold method. Primer sequences are listed in [Table S5](#SD1){ref-type="supplementary-material"}.

### Chromatin Immunoprecipitation (ChIP) and ChIP-Seq {#S21}

ChIP was performed using anti-PU.1 (PA5-17505, Thermo Fisher Scientific), anti-FLAG (clone M2, Sigma), anti-HA (ab9110, Abcam), anti-BCLAF1 (A300-608A, Bethyl Laboratories), control rabbit IgG (Millipore) and control mouse IgG antibodies (clone P3.6.2.8.1, eBioscience) as previously described ([@R7]). Briefly, DNA was cross-linked with 2% formaldehyde for 10 min at room temp (1 × 10^6^ cells/ml). Reaction was stopped with 125 μM Glycine. Cells were lysed with NP-40 and nuclei were frozen in liquid nitrogen then lysed with SDS. DNA was fragmented by sonicating with 30 s pulses for 60 cycles using a Bioruptor (Diagenode). DNA fragmentation was in the range of 200--500 bp and was monitored by agarose gel electrophoresis. Immunoprecipitation was performed with anti-PU.1 (1:100), anti-HA (1 μg), anti-BCLAF1 (2 μg), or control rabbit IgG and Protein A Dynabeads (Life Technologies). DNA was eluted, reverse cross-linked and then purified with QIAquick PCR purification kit (QIAGEN). For ChIP-PCR analysis, PCR was performed using Brilliant II SYBR Green (Agilent) and acquired on an Mx3000P (Stratagene). Primers are listed in [Table S5](#SD1){ref-type="supplementary-material"}. For ChIP-seq analysis, fragmented DNA was quantified using 2100 Bioanalyzer (Agilent Technologies) and DNA libraries were prepared using Illumina TruSeq. Sequencing was performed using an Illumina HiSeq 3000 by the Washington University Genome Technology Access Center. Input controls were used for all samples. FASTQ files were aligned to mm9 using Map with Bowtie for Illumina v. 1.1.2 to the reference genome (NCBI37/mm9) ([@R29]). MACS version 2 was used to call peaks with a tag size set to 45, band width of 300 and a p value of 1 × 10^−5^ ([@R74]). Input. bed files of total reads for MM-ChIP were generated using Convert from BAM to BED tool v0.1.0 in Galaxy V18.09 ([@R1]). Promoter regions were defined as regions extending 12 kb upstream of transcription start site. R package (GenomicRanges) and Bedtools V2.25.0 were used to determine overlapping ChIP peaks ([@R31]; [@R50]). MAnorm using parameters -w 300-s1 50-s2 50 was used to calculate normalized fold changes for each ChIP-seq comparison ([@R64]). A 1.5 fold change magnitude was used to separate enriched and unbiased peaks for each comparison. EaSeq v1.111 was used to generate ratiometric heatmaps from RPM-normalized ChIP-seq signal ([@R32]). Data will be deposited in NCBI's Gene Expression Omnibus.

### Ultra-Low-Input Native ChIP {#S22}

EGFP-negative (−) and EGFP-expressing (+) small pre-B cells were sorted from *SPIC*^*igfp/igfp*^ mice. ULI-NChIP was performed as previously described ([@R11]). Briefly, chromatin was fragmented using micrococcal nuclease (New England Biolabs) at 37°C for 5 mins and diluted in complete immunoprecipitation buffer (20mM Tris-HCl pH 8.0, 2mM EDTA, 15mM NaCl, 0.1% Triton X-100, protease and phosphatase inhibitors). Fragmented chromatin was precleared with Protein A Dynabeads (Life Technologies). Immunoprecipitation was performed with anti-PU.1 (1:100), anti-BCLAF1 (10 μg), or control rabbit IgG and Protein A Dynabeads (Life Technologies). The antibody-beads complex was washed with low salt (20mM Tris-HCl, pH 8.0, 0.1%SDS, 1% Triton X-100, 0.1% deoxycholate, 2mM EDTA and 150mM NaCl) and high salt (20mM Tris-HCl, pH 8.0, 0.1%SDS, 1% Triton X-100, 0.1% deoxycholate, 2mM EDTA and 300mM NaCl) buffer. DNA was eluted in high salt buffer. DNA was purified and ChIP-PCR was performed as above.

### RNA-Seq Analysis {#S23}

RNA was extracted using RNeasy Kit (QIAGEN). Libraries were prepared using Illumina TrueSeq Adpaters and paired-end sequencing was performed using an Illumina HiSeq 3000 by the Washington University Genome Technology Access Center according to the manufacturer's protocols. Sequencing data were analyzed as previously described ([@R3]). Briefly, RNA-seq reads were aligned to mm9 assembly with STAR version 2.0.4b1. Gene counts were derived from uniquely aligned unambiguous reads by Subread-featureCount version 1.4.5. Gene-level counts were imported into the R/Bioconductor package EdgeR and TMM normalization size factors were calculated to adjust for differences in library size ([@R52]). Differential expression analysis was then performed to analyze for differences between conditions using the R/Bioconductor package limma-voom ([@R30]). Results were filtered for only those genes with Benjamini-Hochberg false-discovery rate adjusted p values less than or equal to 0.05. DAVID (Database for Annotation, Visualization and Integrated Discovery, v6.8) was used to test if differentially expressed genes resulted in perturbations in known Gene Ontology (GO) terms and KEGG pathways ([@R26]). Volcano plots were generated using R (ggplot2). Java TreeView Version 1.1.6r4 and R/Bioconductor package heatmap3 were used to display heat-maps ([@R58]; [@R75]). DAVID was used to display annotated KEGG graphs across groups of samples for each GO term or KEGG pathway with a Benjamini-Hochberg false-discovery rate adjusted p value ≤ 0.05.

### Tandem Affinity Purification and MS Analysis {#S24}

FLAG-HA-tagged SPIC and PU.1 were immunoprecipitated using anti-FLAG antibody as previously described with the following modifications ([@R39]; [@R40]). Cells were lysed lysis of cells (1 × 10^9^ cells/1.5 ml) in TAP buffer (50 mM Tris, pH 7.9,150 mM NaCI, 1% NP-40, and protease and phosphatase inhibitor cocktails (Sigma). The lysate was cleared by centrifugation and incubated with anti-FLAG beads (40 μl/10^9^ cells; clone M2; Sigma-Aldrich) for 4 hours. After extensive washing in the same buffer, bound material was eluted with FLAG peptide (Sigma-Aldrich) and analyzed by western blotting. Coomassie-stained bands were cut from SDS-PAGE and sent to Taplin Biological Mass Spectrometry Facility at Harvard Medical School ([taplin.med.harvard.edu](http://taplin.med.harvard.edu)). In-gel trypsin digestion was performed and the detection of complexed proteins was done using Orbitrap ion-trap mass spectrometers (ThermoFisher Scientific). Interacting proteins were identified by matching protein database with acquired fragmentation pattern by using Sequest (ThermoFisher Scientific) ([@R18]).

QUANTIFICATION AND STATISTICAL ANALYSIS {#S25}
---------------------------------------

RNA-seq and ChIP-seq were analyzed for statistical significance using the software packages described above. For all other analyses, statistics and figures were generated using Prism 8 (v8.0.2). P values were generated via Student's t test (unpaired, two-tailed). Error bars are SE. \*p value ≤ 0.05, \*\*p value ≤ 0.01, \*\*\*p value ≤ 0.001, \*\*\*\*p value ≤ 0.0001.

DATA AND CODE AVAILABILITY {#S26}
--------------------------

The ChIP-seq and RNA-seq data generated during this study are available at NCBI Gene Expression Omnibus under accession number GEO: GSE129130.
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![RAG DSB Signals Induce Genome-wide Changes in PU.1 Binding\
(A) qPCR analysis of *Igk* genomic DNA from *Rag1*^−/−^*:Bcl2* (red) and *Art*^−/−^*:Bcl2* (blue) abl pre-B cells treated with imatinib for 48 h. Schematic shows germline (GL) *Igk* locus and unrepaired Jκ1 coding end with location of PCR primers. PCR is normalized to*Rag1*^−/−^*:Bcl2* abl pre-B cells, which do not generate RAG DSBs and have only intact germline *Igk* DNA. Data are representative of three independent experiments.\
(B) Dot plot and heatmap of fold changes and signal Intensity for PU.1 peaks Identified by ChIP-seq In *Rag1*^−/−^*:Bcl2* and *Art*^−/−^*:Bcl2* abl pre-B cells treated with Imatinib for 48 h. Data are from common peaks identified in two replicates for each cell.\
(C) Representative tracks at indicated regions for PU.1 ChIP-seq from (B). ChIP-qPCR validation for PU.1 binding at each locus is also shown. Data are mean and SE for three independent experiments. \*\*p ≤ 0.01 and \*\*\*\*p ≤ 0.0001; ns, not significant.\
See also [Figure S1](#SD1){ref-type="supplementary-material"}.](nihms-1542691-f0002){#F1}

![Expression of SPIC Alters PU.1 Binding\
(A) *Spic* mRNA expression in *Rag1*^−/−^*:Bcl2* and *Art*^−/−^*:Bcl2* ablpre-B cells treated with imatinib for 48 h. *Art*^−/−^*:Bcl2* ablpre-B cells were also treated with vehicle (−) or 15 μM ATM inhibitor KU55933 (+ iATM). Data are relative to *Rag1*^−/−^*:Bcl2* and are mean and SE for three independent experiments.\
(B) *Spic* mRNA expression in *Rag1*^−/−^*:Bcl2:Spic*^*tet*^ abl pre-B cells treated with imatinib alone (−) or with imatinib and 2 μM doxycycline (Dox; +) for 48 h. Data are relative to *Rag1*^−/−^*:Bcl2:Spic*^*tet*^ without doxycycline and are mean and SE for three independent experiments.\
(C) Western blot shows PU.1 and SPIC (determined by anti-FLAG antibody) in *Rag1*^−/−^*:Bcl2:Spic*^*tet*^ abl pre-B cells treated as in (B). Data are representative of three independent experiments.\
(D) Dot plot and heatmap of fold changes and signal intensity for PU.1 peaks identified by ChIP-seq in *Rag1* ^−/−^*:Bcl2:Spic*^*tet*^ abl pre-B cells treated with imatinib alone (− Dox, no SPIC) or with imatinib and 2 μM doxycycline (+ Dox, + SPIC) for 48 h as in (B). Data are from common peaks identified in two replicates for each cell line.\
\*p ≤ 0.05.](nihms-1542691-f0003){#F2}

![SPIC and PU.1 Bind to Identical Genomic Regions\
(A) Dot plot and heatmap of fold changes and signal intensity for PU.1 and SPIC (by anti-HA ChIP) peaks identified by ChIP-seq in *Rag1*^−/−^*:Bcl2:Spic*^*tet*^ abl pre-B cells treated with imatinib for 48 h in the absence (for PU.1 ChIP) or presence (for SPIC ChIP) of 2 μM doxycycline (Dox). Data are from common peaks identified in two replicates of each cell line.\
(B) Representative ChIP-seq binding of PU.1 and SPIC at indicated regions. PU.1 ChIP-seq was performed in *Rag1*^−/−^*:Bcl2:Spic*^*tet*^ abl pre-B cells treated with imatinib alone (− Dox, no SPIC) or with imatinib and doxycycline to induce expression of SPIC(+ Dox, + SPIC) for 48 h. ChIP-seq for SPIC was performed as in A in *Rag1*^−/−^*:Bd2:Spic*^*tet*^ abl pre-B cells treated with imatinib and doxycycline for 48 h.\
(C) ChIP-qPCR validation for PU.1 and SPIC binding at each locus shown in (B). Data are mean and SE for three independent experiments. \*\*p ≤ 0.01, \*\*\*p ≤ 0.001, and \*\*\*\*p ≤ 0.0001.\
(D) Nucleotide overlap between PU.1 and SPIC peaks identified in (A). Peaks were grouped in bins on the basis of percentage of overlap as shown.\
(E) Enrichment of PU.1 and SPIC binding across genomic regions on the basis of ChIP-seq data in (A).\
See also [Figure S2](#SD1){ref-type="supplementary-material"}.](nihms-1542691-f0004){#F3}

![SPIC Recruits BCLAF1 to Chromatin\
(A) FLAG-HA-SPIC and FLAG-HA-PU.1 were immunoprecipitated from *Art*^−/−^*:Bcl2:Spic*^*tet*^ and *Art*^*-*−/−^*:Bcl2:Pu.1*^*tet*^, respectively, after treatment with imatinib and 2 μM doxycycline for 48 h. Scatterplot shows number of total peptides per protein identified by mass spectrometry analysis of co-immunoprecipitation of SPIC (y axis) versus PU.1 (x axis).\
(B) FLAG-HA-tagged SPIC and FLAG-HA-tagged PU.1 were immunoprecipitated from *Art*^−/−^*:Bcl2: Spic*^*tet*^ and *Art*^−/−^*:Bcl2:Pu.1*^*tet*^ abl pre-B cells, respectively, treated as in (A). IP samples were immunoblotted (IB) for BCLAF1, IRF4, IRF8, and FLAG. Asterisk indicates non-specific band.\
(C) BCLAF1 was immunoprecipitated from *Art*^−/−^*:Bcl2:Spic*^*tet*^ (*Spic*^*tet*^) and *Art*^−/−^*:Bcl2:Pu.1*^*tet*^ (*Pu.1*^*tet*^) abl pre-B cells treated as in (A). IP samples were immunoblotted for BCLAF1 and FLAG.\
(D) Dot plot and heatmap of fold changes and signal intensity for BCLAF1 and SPIC peaks (by anti-HA ChIP as in [Figure 3A](#F3){ref-type="fig"}) identified by ChIP-seq in *Rag1*^−/−^*:Bcl2:Spic*^*tet*^ abl pre-B cells treated with imatinib and 2 μM doxycycline for 48 h. Data are from common peaks identified in two replicates of each cell line.\
(E) ChIP-qPCR of BCLAF1 binding at the *Syk* promoter in *Rag1*^−/−^*:Bcl2:Spic*^*tet*^ abl pre-B cells treated with imatinib for 48 h in the absence (−) or presence (+) of 2 μM doxycycline (Dox) to induce SPIC expression.\
(F) Re-ChIP for BCLAF1 after primary ChIP for SPIC or PU.1 (using anti-HA antibodies) in *Rag1*^−/−^*:Bcl2:Spic*^*tet*^ or *Rag1*^−/−^*:Bcl2:Pu.1*^*tet*^ abl pre-B cells, respectively, treated with imatinib and 2 μM doxycycline for 48 h.\
(G) ChIP-qPCR of BCLAF1 binding at the *Syk* promoter in *Rag1*^−/−^*:Bcl2* and *Art*^−/−^*:Bcl2* abl pre-B cells treated with imatinib for 48 h.\
Data in (A--C) are representative of three independent experiments. Data in (E--G) are mean and SE for three independent experiments. \*\*p ≤ 0.01, \*\*\*p ≤ 0.001, and \*\*\*\*p ≤ 0.0001.\
See also [Figure S3](#SD1){ref-type="supplementary-material"} and [Table S1](#SD2){ref-type="supplementary-material"}.](nihms-1542691-f0005){#F4}

![SPIC and BCLAF1 Regulate Gene Expression in Pre-B Cells in Response to RAG DSBs\
(A) Volcano plot of gene expression changes (fold change ≥ 2, p ≤ 0.05) between *Rag1*^−/−^*:Bcl2:Spic*^*tet*^ abl pre-B cells with and without SPIC induction. RNA-seq was performed on *Rag1*^−/−^*:Bcl2:Spic*^*tet*^ abl pre-B cells treated with imatinib alone (− SPIC) or with imatinib and 2 μM doxycycline (+ SPIC) for 48 h. Data are from two independent cultures for each treatment.\
(B) Western blot of BCLAF1 in *Rag1*^−/−^*:Bcl2:Spic*^*tet*^ abl pre-B cells transduced with a retrovirus expressing a scrambled short hairpin RNA (shRNA) (−) or shBclaf1 (+) and then treated with imatinib and 2 μM doxycycline for 48 h (to induce SPIC). Data are representative of three independent experiments.\
(C) Heatmap of gene expression changes (fold change ≥ 2, p ≤ 0.05) among *Rag1*^−/−^*:Bcl2:Spic*^*tet*^ cells without SPIC, *Rag1*^−/−^*:Bcl2:Spic*^*tet*^ cells expressing SPIC, and *Rag1*^−/−^*:Bcl2:Spic*^*tet*^ cells expressing SPIC and shBclaf1. Cells were treated as in (A) and (B). Columns represent independent cultures for each cell line and treatment as indicated. Representative gene are delineated to the right.\
(D) ChIP-qPCR of SPIC binding at the *Syk* promoter in *Rag1*^−/−^*:Bcl2:Spic*^*tet*^ cells expressing a scrambled shRNA (−) or shBclaf1 (+) and treated as in (B). Data are mean and SE for three independent experiments. ns, not significant.\
(E) Heatmap of gene expression changes (fold change ≥ 2, p ≤ 0.05) among *Rag1*^−/−^*:Bcl2, Art*^−/−^*:Bcl2,* and *Art*^−/−^*:Bcl2* abl pre-B cells expressing shBclaf1. *Art*^−/−^*:Bcl2* abl pre-B cells were transduced with a retrovirus expressing shBclaf1. RNA sequencing (RNA-seq) was performed on all cells after treatment with imatinib for 48 h. Columns represent independent cultures for each cell line as indicated. Representative genes are delineated to the right.\
(F) Flow diagram showing identification of genes regulated by RAG DSBs, SPIC, and BCLAF1 in pre-B cells.\
(G) Representative tracks at genes identified in F from RNA-seq in (C) and (E).\
See also [Figures S4](#SD1){ref-type="supplementary-material"} and [S5](#SD1){ref-type="supplementary-material"} and [Tables S2](#SD3){ref-type="supplementary-material"}, [S3](#SD4){ref-type="supplementary-material"}, and [S4](#SD1){ref-type="supplementary-material"}.](nihms-1542691-f0006){#F5}

![BCLAF1 Regulates SYK Expression in Primary Pre-B Cells\
(A-C) *Art*^−/−^*:μIgh:Bcl2* pre-B cells were transduced with a retrovirus expressing a scrambled shRNA (−) or shBclaf1 (+) and then subsequently withdrawn from IL-7.\
(A and B) *Spic* and *Syk* mRNA expression assessed in indicated small pre-B cells 2 days after IL-7 withdrawal. Data are mean and SE for three independent experiments.\
(C) Western blot of SYK and BCLAF1 in indicated small pre-B cells 2 days after IL-7 withdrawal. Data are representative of three independent experiments.\
(D) Flow cytometric analysis showing EGFP (y axis) and FSC (x axis) in bone marrow pre-B cells (B220^lo^CD43^−^IgM^−^) from wild-type and *Spic*^*igfp*/*igfp*^ mice. Data are representative of five independent experiments.\
(E) Percentage of EGFP-positive small pre-B cells in *Spic*^*igfp*/*igfp*^ (circles) and *Atm*^−/−^*:Spic*^*igfp*/*igfp*^ (squares) mice was quantified by flow cytometry as in (D). Data are mean and SE from three independent mice of each genotype.\
(F--H) *Syk* mRNA expression (F), ChIP-PCR of PU.1 at *Syk* promoter (G), and ChIP-PCR of BCLAF1 at *Syk* promoter (H) in EGFP-negative (−) and EGFP-expressing (+) small pre-B cells sorted from *Spic*^*igfp*/*igfp*^ mice. Data in (F) are the mean and SE from three independent experiments. Data in (G) and (H) are representative of two independent experiments.\
\*p ≤ 0.05, \*\*p ≤ 0.01, \*\*\*p ≤ 0.001,\*\*\*\*p ≤ 0.0001; ns, not significant.](nihms-1542691-f0007){#F6}

![BCLAF1 Regulates Large to Small Pre-B Cell Transition\
(A) Western blot of BCLAF1 in sorted CD19− (non-B cell) and CD19+ B cell populations from bone marrow of 5-week-old *Bclaf1*^*f/f*^*:Mb1-cre* mice. Data are representative of three independent mice.\
(B) Flow cytometric analysis of BrdU incorporation (y axis) and DNA content (7AAD, x axis) performed 24 h after IL-7 withdrawal. Percentage of cells that entered S phase during BrdU labeling (box) is indicated. Data are representative of at least three independent experiments.\
(C) Percentage of cells that entered S phase in cell cycle analysis performed in (B). Data are mean and SE for four independent experiments.\
(D) *Syk* mRNA expression 24 h after IL-7 withdrawal. Data are mean and SE for three independent experiments.\
(E) Quantitation of flow cytometric analysis of pro-B cells (B220^lo^IgM^−^CD43^+^) and pre-B cells (B220^lo^IgM^−^CD43^−^) in bone marrow of 5-week-old *Bclaf1*^*f/f*^ (black bars, n = 12), *Mb1-cre* (gray bars, n = 9), and *Bclaf1*^*f/f*^*:Mb1-cre* (white bars, n = 12) mice. Large and small pre-B cells were gated on the basis of forward-scatter and side-scatter characteristics.\
(F) *Syk* mRNA expression in small and large pre-B cells sorted from 5-week-old *Bclaf1*^*f/f*^ (black bars, n = 4), *Mb1-cre* (gray bars, n = 5), and *Bclaf1*^*f/f*^*:Mb1-cre* (white bars, n = 5) mice.\
Data in (E) and (F) are mean and SE for indicated numbers of mice. \*p ≤ 0.05, \*\*p ≤ 0.01, and \*\*\*p ≤ 0.001; ns, not significant.\
See also [Figure S6](#SD1){ref-type="supplementary-material"}.](nihms-1542691-f0008){#F7}

  REAGENT or RESOURCE                                                         SOURCE                      IDENTIFIER
  --------------------------------------------------------------------------- --------------------------- --------------------------------------------------------------------------------------------
  Antibodies                                                                                              
  APC human CD25 Clone BC96                                                   BioLegend                   Cat\# 302610; RRID: AB_314280
  biotin conjugated anti-hCD2                                                 BD Biosciences              Cat\# 555325; RRID: AB_395732
  PE- anti-hCD25 Clone BC96                                                   BioLegend                   Cat\# 302605; RRID: AB_314275
  FITC-conjugated anti-CD45R/B220 (clone RA3--6B2)                            BD Biosciences              Cat\# 553088; RRID: AB_394618
  PE-conjugated anti-CD43 (clone S7)                                          BD Biosciences              Cat\# 553271: RRID: AB_394748
  FITC-conjugated anti-CD43 (clone S7)                                        BD Biosciences              Cat\# 553270; RRID: AB_394747
  PE-Cy7-conjugated anti-CD45/B220 (clone RA3--6B2)                           BD Biosciences              Cat \# 552772: RRID: AB_394458
  allophycocyanin (APC)-conjugated anti-IgM (clone II/41)                     BD Biosciences              Cat \# 550676; RRID: AB_398464
  PE-conjugated anti-hCD2                                                     BD Biosciences              Cat\# 555327; RRID: AB_395734
  APC-conjugated anti-hCD2                                                    BD Biosciences              Cat\# 560642; RRID: AB_1727443
  Anti-SYK (clone D1I5Q)                                                      Cell Signaling Technology   Cat\# 12358; RRID: AB_2687923
  Anti-BCLAF1 antibody (A300--608A)                                           Bethyl Laboratories         Cat\# A300--608A; RRID: AB_513581
  PU.1 (PA5--17505)                                                           Thermo Fisher               Cat\# 17505; RRID: AB\_?0989141
  Anti-GAPDH                                                                  Cell Signaling              Cat\# 5174; RRID: AB_10622025
  anti-FLAG (clone M2)                                                        Sigma                       Cat\# 1804; RRID: AB_262044
  HRP-conjugated anti-mouse IgG                                               Cell Signaling              Cat \# 7074; RRID: AB_2099233
  HRP-conjugated anti-rabbit IgG                                              Cell Signaling              Cat\# 7065; RRID: AB_10890862
  Anti-HA                                                                     Abcam                       Cat\# ab9110; RRID: AB_307019
  control rabbit IgG                                                          Millipore                   Cat\# 06--371; RRID: AB_390146
  Chemicals, Peptides, and Recombinant Proteins                                                           
  SuperScriptII                                                               Life Technologies           18064--014
  Brilliant II SYBR Green                                                     Agilent                     600828
  Interleukin-7 (IL-7)                                                        Miltenyi Biotec             130--098--222
  Imatinib                                                                    Novartis                    00078--0438--15
  Lipofectamine 2000                                                          Life Technologies           11668--019
  PEG-8000                                                                    Fisher                      P156--500
  Sequabrene                                                                  Sigma                       S 2667
  ATM inhibitor KU55933                                                       Tocris                      3544
  Micrococcal nuclease                                                        New England Biolabs         M0247S
  Critical Commercial Assays                                                                              
  RNeasy                                                                      QIAGEN                      74104
  Protein A Dynabeads                                                         Thermo Fisher Scientific    10002D
  QIAquick PCR purification kit                                               QIAGEN                      28106
  Anti-biotin magnetic beads                                                  Miltenyi Biotec             130--090--485
  Anti-hCD25 magnetic beads                                                   Miltenyi Biotec             130--092--983
  Anti-hCD2 magnetic beads                                                    Miltenyi Biotec             130--091--114
  High sensitivity DNA ChiPs                                                  Agilent Technologies        5067--4626
  Magnetic Separation columns                                                 Miltenyi Biotec             130--042--201
  ECL                                                                         Pierce                      32209
  ECL Prime                                                                   GE Healthcare               RPN2232
  FITC BrdU Flow Kit                                                          BD Bioscience               559619
  Deposited Data                                                                                          
  ChiP-seq                                                                    This paper                  NCBI GEO \#: GSE129130 (subseries: GSE129124)
  RNA-seq                                                                     This paper                  NCBI GEO \#: GSE129130 (subseries: GSE129129)
  Experimental Models: Cell Lines                                                                         
  *Art^−/−^:Bcl2* abl pre-B cell                                              Barry Sleckman              N/A
  *Rag^−/−^:Bcl2* abl pre-B cell                                              Barry Sleckman              N/A
  PlatE                                                                       Cell Biolabs, Inc           RV-101
  Experimental Models: Organisms/Strains                                                                  
  *Mb1-cre* (Cd79a^tm1(cre)*Reth*^) mice                                      Jackson Laboratory          20505
  *Bclaf1^f/f^* mice                                                          KOMP Repository             *Bclaf1^tm1a^*
  *Rag1^−/−^:μIgh:Bcl2*                                                       Barry Sleckman              N/A
  *Art^−/−^:μIgh:Bcl2*                                                        Barry Sleckman              N/A
  B6.Cg-Tg(ACTFLPe)9205Dym/J                                                  Jackson Laboratory          5703
  *Spic^igfp/igfp^*                                                           Kenneth Murphy              N/A
  Oligonucleotides                                                                                        
  Primers are listed in [Table S5](#SD1){ref-type="supplementary-material"}   This paper                  N/A
  Recombinant DNA                                                                                         
  MSCV-hCD2-mir30 vector                                                      Mark Schlissel              N/A
  pFLRU-TRE-FLAG-HA-PU.1-Ubc-rtTA-IRES-Thy1.2                                 This paper                  N/A
  pFLRU-TRE-FLAG-HA-SPIC-Ubc-rtTA-IRES-Thy1.2                                 This paper                  N/A
  pCMV-VSV-G                                                                  [@R69]                      Addgene \#8454
  pCMV-d8.2R dvpr                                                             [@R69]                      Addgene \#8455
  Software and Algorithms                                                                                 
  Bowtie v. 1.1.2                                                             [@R29]                      <http://bowtie-bio.sourceforge.net/bowtie2/index.shtml> RRID:SCR_005476
  MACS version 2                                                              [@R74]                      <http://liulab.dfci.harvard.edu/MACS/> RRID:SCR_013291
  Galaxy V18.09                                                               [@R1]                       <https://usegalaxy.org> RRID:SCR_006281
  GenomicRanges                                                               [@R31]                      <https://www.bioconductor.org/packages//2.10/bioc/html/GenomicRanges.html> RRID:SCR_000025
  Bedtools V2.25.0                                                            [@R50]                      <https://github.com/arq5x/bedtools2>. RRID:SCR_006646
  EdgeR- TMM                                                                  [@R52]                      <http://bioconductor.org/biocLite.R> RRID:SCR_012802
  Limma-Voom                                                                  [@R30]                      <https://omictools.com/limma-tool> RRID:SCR_010943
  TreeView Version 1.1.6r4                                                    [@R58]                      <https://bitbucket.org/TreeView3Dev/treeview3/> RRID:SCR_016916
  Heatmap3                                                                    [@R75]                      <https://bioconductor.org/packages/release/bioc/html/heatmaps.html>
  DAVID (v.6.8)                                                               [@R26]                      <https://david.ncifcrf.gov> RRID:SCR_001881
  EaSeq (v1.111)                                                              [@R32]                      <http://easeq.net>
  MAnorm                                                                      [@R64]                      <http://bcb.dfci.harvard.edu/~gcyuan/MAnorm/MAnorm.htm> RRID:SCR_010869
  Prism 8 (v8.0.2)                                                            GraphPad Software           <https://www.graphpad.com>

###### Highlights

-   RAG DNA breaks upregulate SPIC, which induces genome-wide changes in PU.1 activity

-   SPIC binds to gene-regulatory elements, resulting in loss of PU.1 at these regions

-   SPIC complexes with BCLAF1 to suppress transcription in response to RAG DNA breaks

-   SPIC/BCLAF1 inhibits SYK and promotes transition from large to small pre-B cells
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